These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 33435908)

  • 21. Association of Disorganization of Retinal Inner Layers With Visual Acuity Response to Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Secondary to Retinal Vein Occlusion.
    Babiuch AS; Han M; Conti FF; Wai K; Silva FQ; Singh RP
    JAMA Ophthalmol; 2019 Jan; 137(1):38-46. PubMed ID: 30286219
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison between Ozurdex and intravitreal anti-vascular endothelial growth factor treatment for retinal vein occlusion-related macular edema: A systematic review and meta-analysis of randomized controlled trials.
    Hu Q; Li H; Xu W; Du Y; Ma C; He J
    Indian J Ophthalmol; 2019 Nov; 67(11):1800-1809. PubMed ID: 31638037
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Individualized Ranibizumab Regimen Driven by Stabilization Criteria for Central Retinal Vein Occlusion: Twelve-Month Results of the CRYSTAL Study.
    Larsen M; Waldstein SM; Boscia F; Gerding H; Monés J; Tadayoni R; Priglinger S; Wenzel A; Barnes E; Pilz S; Stubbings W; Pearce I;
    Ophthalmology; 2016 May; 123(5):1101-11. PubMed ID: 26896124
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship Between Visual Acuity and Retinal Thickness During Anti-Vascular Endothelial Growth Factor Therapy for Retinal Diseases.
    Ou WC; Brown DM; Payne JF; Wykoff CC
    Am J Ophthalmol; 2017 Aug; 180():8-17. PubMed ID: 28549848
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Individualized Stabilization Criteria-Driven Ranibizumab versus Laser in Branch Retinal Vein Occlusion: Six-Month Results of BRIGHTER.
    Tadayoni R; Waldstein SM; Boscia F; Gerding H; Pearce I; Priglinger S; Wenzel A; Barnes E; Gekkieva M; Pilz S; Monés J;
    Ophthalmology; 2016 Jun; 123(6):1332-44. PubMed ID: 27039022
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ranibizumab in preproliferative (ischemic) central retinal vein occlusion: the rubeosis anti-VEGF (RAVE) trial.
    Brown DM; Wykoff CC; Wong TP; Mariani AF; Croft DE; Schuetzle KL;
    Retina; 2014 Sep; 34(9):1728-35. PubMed ID: 24914476
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravitreal ranibizumab for macular edema secondary to retinal vein occlusion.
    Kim M; Yu SY; Kim ES; Bae SH; Park JH; Yu HG; Kwak HW
    Ophthalmologica; 2012; 227(3):132-8. PubMed ID: 22212151
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EARLY CRT MONITORING USING TIME-DOMAIN OPTICAL COHERENCE TOMOGRAPHY DOES NOT ADD TO VISUAL ACUITY FOR PREDICTING VISUAL LOSS IN PATIENTS WITH CENTRAL RETINAL VEIN OCCLUSION TREATED WITH INTRAVITREAL RANIBIZUMAB: A Secondary Analysis of Trial Data.
    Bell KJ; Hayen A; Glasziou P; Mitchell AS; Farris M; Wright J; Duerr HP; Mitchell P; Irwig L
    Retina; 2017 Mar; 37(3):509-514. PubMed ID: 27548351
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Photocoagulation or sham laser in addition to conventional anti-VEGF therapy in macular edema associated with TelCaps due to diabetic macular edema or retinal vein occlusion (TalaDME): a study protocol for a multicentric, French, two-group, non-commercial, active-control, observer-masked, non-inferiority, randomized controlled clinical trial.
    Dupas B; Castro-Farias D; Girmens JF; Eginay A; Couturier A; Villeroy F; Delyfer MN; Creuzot-Garcher C; Giocanti-Auregan A; Béral L; Arndt C; Mesnard C; Vicaut E; Chaumet-Riffaud P; Durand-Zaleski I; Paques M
    Trials; 2024 Apr; 25(1):273. PubMed ID: 38649937
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcome of "treat and monitor" regimen of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion.
    Pichi F; Elbarky AM; Elhamaky TR
    Int Ophthalmol; 2019 Jan; 39(1):145-153. PubMed ID: 29274022
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-life clinical data for dexamethasone and ranibizumab in the treatment of branch or central retinal vein occlusion over a period of six months.
    Winterhalter S; Eckert A; Vom Brocke GA; Schneider A; Pohlmann D; Pilger D; Joussen AM; Rehak M; Grittner U
    Graefes Arch Clin Exp Ophthalmol; 2018 Feb; 256(2):267-279. PubMed ID: 29185099
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of clinical efficacy of intravitreal ranibizumab with and without triamcinolone acetonide in macular edema secondary to central retinal vein occlusion.
    Fan C; Wang Y; Ji Q; Zhao B; Xie J
    Curr Eye Res; 2014 Sep; 39(9):938-43. PubMed ID: 24635755
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcome of intravitreal dexamethasone implant for the treatment of ranibizumab-resistant macular edema secondary to retinal vein occlusion.
    Manousaridis K; Peter S; Mennel S
    Int Ophthalmol; 2017 Feb; 37(1):47-53. PubMed ID: 27043320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Two-Year Efficacy of Ranibizumab Plus Laser-Induced Chorioretinal Anastomosis vs Ranibizumab Monotherapy for Central Retinal Vein Occlusion: A Randomized Clinical Trial.
    McAllister IL; Smithies LA; Chen FK; Mackey DA; Sanfilippo PG
    JAMA Ophthalmol; 2018 Dec; 136(12):1391-1397. PubMed ID: 30347030
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham-controlled ROCC study.
    Kinge B; Stordahl PB; Forsaa V; Fossen K; Haugstad M; Helgesen OH; Seland J; Stene-Johansen I
    Am J Ophthalmol; 2010 Sep; 150(3):310-4. PubMed ID: 20591399
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Two-Year Follow-up Results of Patients with Macular Oedema Due to Retinal Vein Occlusion Treated with Ranibizumab].
    Hladíková Z; Klofáčová E; Kalvodová B
    Cesk Slov Oftalmol; 2017; 73(2):43-51. PubMed ID: 28931295
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Time to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: BRAVO and CRUISE trials.
    Thach AB; Yau L; Hoang C; Tuomi L
    Ophthalmology; 2014 May; 121(5):1059-66. PubMed ID: 24424249
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A 12-month, multicenter, parallel group comparison of dexamethasone intravitreal implant versus ranibizumab in branch retinal vein occlusion.
    Bandello F; Augustin A; Tufail A; Leaback R
    Eur J Ophthalmol; 2018 Nov; 28(6):697-705. PubMed ID: 29631435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pre-treatment clinical features in central retinal vein occlusion that predict visual outcome following intravitreal ranibizumab.
    Brogan K; Precup M; Rodger A; Young D; Gilmour DF
    BMC Ophthalmol; 2018 Feb; 18(1):37. PubMed ID: 29426292
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-VEGF treatment in branch retinal vein occlusion: a real-world experience over 4 years.
    Rezar S; Eibenberger K; Bühl W; Georgopoulos M; Schmidt-Erfurth U; Sacu S;
    Acta Ophthalmol; 2015 Dec; 93(8):719-25. PubMed ID: 26109209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.